Evidence map›Paper›PMID 38332179›Full record

ArticleBritish journal of cancer2024

Late endocrine diseases in survivors of adolescent and young adult cancer in California: a population-based study.

Renata Abrahão, Ann Brunson, Kathryn J Ruddy, Qian Li, Judy Li, Mabel M Ryder, Jessica Chubak, Hazel B Nichols, Candice A M Sauder, Marlaine F Gray and 3 more

Open access · greenAbstract read
In one paragraph

Article in British journal of cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
7.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 1 country.

Renata AbrahãoCenter for Oncology Hematology Outcomes Research and Training (COHORT), Division of Hematology and Oncology, University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA. rabrahao@ucdavis.edu.ORCID 0000-0002-1644-0313
Ann BrunsonCenter for Oncology Hematology Outcomes Research and Training (COHORT), Division of Hematology and Oncology, University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA.
Kathryn J RuddyDepartment of Oncology, Mayo Clinic, Rochester, MN, USA.
Qian LiCenter for Oncology Hematology Outcomes Research and Training (COHORT), Division of Hematology and Oncology, University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA.
Judy LiCenter for Oncology Hematology Outcomes Research and Training (COHORT), Division of Hematology and Oncology, University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA.
Mabel M RyderDepartment of Oncology, Mayo Clinic, Rochester, MN, USA.
Jessica ChubakKaiser Permanente Washington Health Research Institute, Seattle, WA, USA.
Hazel B NicholsDepartment of Epidemiology, University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC, USA.
Candice A M SauderDivision of Surgical Oncology, Department of Surgery, University of California Davis Medical Center, Sacramento, CA, USA.
Marlaine F GrayKaiser Permanente Washington Health Research Institute, Seattle, WA, USA.
Erin E HahnKaiser Permanente Southern California, Research and Evaluation, Pasadena, CA, USA.
Ted WunCenter for Oncology Hematology Outcomes Research and Training (COHORT), Division of Hematology and Oncology, University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA.ORCID 0000-0001-6383-7172
Theresa H M KeeganCenter for Oncology Hematology Outcomes Research and Training (COHORT), Division of Hematology and Oncology, University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA.
UC Davis Comprehensive Cancer CenterKaiser Permanente Washington Health Research Institute · USMayo Clinic in Arizona · USUniversity of California Davis Medical Center · USKaiser Permanente · USUniversity of North Carolina at Chapel Hill · US

Funding

UNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Stephanie Engel · 2001 to 2026
$36.3M
Project 3: Chronic Medical Conditions and Late Effects in the AYA Cancer PopulationP01CA233432 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI CHUBAK, JESSICA, HAHN, ERIN ELIZABETH · 2020 to 2025
$10.5M
NCI NIH HHS P01 CA233432NIEHS NIH HHS P30 ES010126
6 · The paper itself

Abstract

backgroundCancer survivors have increased risk of endocrine complications, but there is a lack of information on the occurrence of specific endocrinopathies at the population-level.

methodsWe used data from the California Cancer Registry (2006-2018) linked to statewide hospitalisation, emergency department, and ambulatory surgery databases. We estimated the cumulative incidence of and factors associated with endocrinopathies among adolescents and young adults (AYA, 15-39 years) who survived ≥2 years after diagnosis.

resultsAmong 59,343 AYAs, 10-year cumulative incidence was highest for diabetes (4.7%), hypothyroidism (4.6%), other thyroid (2.2%) and parathyroid disorders (1.6%). Hypothyroidism was most common in Hodgkin lymphoma, leukaemia, breast, and cervical cancer survivors, while diabetes was highest among survivors of leukaemias, non-Hodgkin lymphoma, colorectal, cervical, and breast cancer. In multivariable models, factors associated with increased hazard of endocrinopathies were treatment, advanced stage, public insurance, residence in low/middle socioeconomic neighbourhoods, older age, and non-Hispanic Black or Hispanic race/ethnicity. Haematopoietic cell transplant was associated with most endocrinopathies, while chemotherapy was associated with a higher hazard of ovarian dysfunction and hypothyroidism.

conclusionsWe observed a high burden of endocrinopathies among AYA cancer survivors, which varied by treatment and social factors. Evidence-based survivorship guidelines are needed for surveillance of these diseases.

Indexed as

Diabetes MellitusHematopoietic Stem Cell TransplantationHodgkin DiseaseHypothyroidismNeoplasmsAdolescentCaliforniaHumansSurvivorsYoung Adult

Identifiers

PMID38332179
PMCPMC10991490
OpenAlexW4391653767

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.